{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:32:18Z","timestamp":1782739938742,"version":"3.54.5"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,19]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>The anaplastic lymphoma kinase (ALK) gene fusion occurs in approximately 3% to 7% of nonsmall cell lung cancer (NSCLC), in which occurs approximately 23% to 31% of brain metastasis patients in poor prognosis. ALK tyrosine kinase inhibitors have shown efficacy in treating ALK-positive (ALK+) NSCLC. More than 90 distinct subtypes of ALK fusions have been identified through sequencing technique and would lead to significant differences in clinical efficacy, it is necessary to guide clinical treatment effectively by gene detection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 56-year-old nonsmoking female admitted to hospital due to cough, expectoration, and chest pain. Chest computed tomography revealed a space-occupying lesion in the upper left lobe (5.0 cm\u2005\u00d7\u20052.4 cm\u2005\u00d7\u20052.9\u2009cm), multiple enlarged lymph nodes in mediastinum 3A and 5 (largest size 1.5 cm\u2005\u00d7\u20051.4\u2009cm), and evidence of thoracic vertebral metastasis, brain magnetic resonance imaging also showed brain metastasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Lung adenocarcinoma with brain metastasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient initially received conventional first-line chemotherapy, which led to a deteriorated condition. Blood-base liquid biopsy by next-generation sequencing resulted in double ALK fusions, in which with a neo-partner of lncRNA (LOC399815-ALK). Following subsequent treatment with Alectinib and stereotactic radiotherapy (CyberKnife) was subsequently employed to manage the brain metastatic lesions, resulting in a substantial decreased in both the number and size of tumor lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient\u2019s response to therapy efficacy resulted in a substantial decreased in both the number and size of tumor lesions that assessed comprehensively evaluated through computed tomography imaging and ctDNA sequencing. Patient\u2019s condition has been under control for over 29 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Liquid biopsy may reveal the rare fusion forms of ALK, precisely guiding personalized treatment, and providing a reference method for longitudinal monitoring and efficacy evaluation of ALK-tyrosine kinase inhibitors in NSCLC patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036992","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T21:02:10Z","timestamp":1705698130000},"page":"e36992","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-EML4 in combined treatment of Alectinib and CyberKnife: A case report"],"prefix":"10.1097","volume":"103","author":[{"given":"Yumei","family":"Li","sequence":"first","affiliation":[{"name":"Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijin","family":"Lu","sequence":"additional","affiliation":[{"name":"Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yao","sequence":"additional","affiliation":[{"name":"Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchuang","family":"Huang","sequence":"additional","affiliation":[{"name":"Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huang","sequence":"additional","affiliation":[{"name":"Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[{"name":"Guangxi Medical University Cancer Hospital, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5079-402X","authenticated-orcid":false,"given":"Shaochen","family":"Cheng","sequence":"additional","affiliation":[{"name":"HaploX Biotechnology, Shenzhen, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250505","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.critrevonc.2017.12.015","article-title":"Precision medicine in ALK rearranged NSCLC: a rapidly evolving scenario.","volume":"122","author":"Addeo","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"R2-20250505","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/1759-7714.14345","article-title":"Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.","volume":"13","author":"Gao","year":"2022","journal-title":"Thorac Cancer"},{"key":"R3-20250505","first-page":"100015","article-title":"Catalog of 5\u2019 fusion partners in ALK-positive NSCLC Circa 2020.","volume":"1","author":"Ou","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"R4-20250505","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non\u2013small-cell lung cancer.","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20250505","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.onc.1200849","article-title":"Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.","volume":"14","author":"Iwahara","year":"1997","journal-title":"Oncogene"},{"key":"R6-20250505","doi-asserted-by":"crossref","first-page":"100571","DOI":"10.1016\/j.currproblcancer.2020.100571","article-title":"Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: a multicenter study from India.","volume":"44","author":"Patel","year":"2020","journal-title":"Curr Probl Cancer"},{"key":"R7-20250505","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jtho.2018.12.002","article-title":"Efficacy of alectinib in patients with ALK-positive NSCLC and symptomatic or large CNS metastases.","volume":"14","author":"Lin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R8-20250505","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nature13556","article-title":"Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity.","volume":"514","author":"Marusyk","year":"2014","journal-title":"Nature"},{"key":"R9-20250505","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nm.3886","article-title":"Subclonal diversification of primary breast cancer revealed by multiregion sequencing.","volume":"21","author":"Yates","year":"2015","journal-title":"Nat Med"},{"key":"R10-20250505","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2016.04.005","article-title":"Diagnostics based on nucleic acid sequence variant profiling: PCR, hybridization, and NGS approaches.","volume":"105","author":"Khodakov","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"R11-20250505","doi-asserted-by":"crossref","first-page":"65997","DOI":"10.18632\/oncotarget.19627","article-title":"Integrated analysis of competing endogenous RNA network revealing lncRNAs as potential prognostic biomarkers in human lung squamous cell carcinoma.","volume":"8","author":"Sui","year":"2017","journal-title":"Oncotarget"},{"key":"R12-20250505","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/1535-7163.MCT-17-0472","article-title":"ALK inhibitor response in melanomas expressing EML4-ALK fusions and alternate ALK isoforms.","volume":"17","author":"Couts","year":"2018","journal-title":"Molecular cancer therapeutics"},{"key":"R13-20250505","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1016\/j.wneu.2022.06.057","article-title":"Mean brain dose remains uninfluenced by the lesion number for gamma knife stereotactic radiosurgery for 10+ metastases.","volume":"165","author":"Sita","year":"2022","journal-title":"World Neurosurg"},{"key":"R14-20250505","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/cancers12040947","article-title":"Genomic profiling of circulating tumor DNA predicts outcome and demonstrates tumor evolution in ALK-positive non-small cell lung cancer patients.","volume":"12","author":"Madsen","year":"2020","journal-title":"Cancers"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T20:03:07Z","timestamp":1746475387000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036992","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}